BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Small molecule tyrosine kinase inhibitors (TKIs) that directly suppress BCR-ABL activity are currently used to treat of CML [7, 8]; however, resistance and intolerance to TKIs prevent a full therapeutic benefit in 20 -30 % of patients [1, 9].